Glovista Investments’s Pfizer PFE Stock Holding History

Glovista Investments’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-11,881	Closed	-$465K	–	95
2021 Q2	$465K	Hold	11,881	–	–	0.11%	84
2021 Q1	$430K	Buy	+11,881	New	+$422K	0.13%	82
2015 Q1	–	Sell	-32,316	Closed	-$955K	–	92
2014 Q4	$955K	Buy	+32,316	New	+$927K	0.12%	38
2014 Q2	–	Sell	-6,623	Closed	-$202K	–	100
2014 Q1	$202K	Buy	+6,623	New	+$197K	0.03%	83

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Glovista Investments's PFE Position: Q3 2021 in Review

Glovista Investments sold out of Pfizer (PFE) in Q3 2021, closing a stake of 11,881 shares — an estimated $465K sold.

Glovista Investments first reported a position in PFE in Q1 2014 and held it in 4 quarters. The position peaked at $955K in Q4 2014. 2,803 funds tracked by Wall St. Rank hold PFE as of Q3 2021.

Glovista Investments reported no remaining Pfizer position as of Q3 2021 after selling out during the quarter.
Glovista Investments sold 11,881 Pfizer shares in Q3 2021, an estimated $465K.
Glovista Investments first reported a position in Pfizer in Q1 2014 and held it in 4 quarters.
Glovista Investments's Pfizer position peaked at $955K in Q4 2014.
2,803 funds tracked by Wall St. Rank held Pfizer as of Q3 2021.

Based on Glovista Investments's 13F filing for Q3 2021, filed 12 Nov 2021.